The FDA has approved a second bispecific antibody to treat patients with diffuse large B-cell lymphoma, as well as Linzess to treat children with constipation. Additionally, an FDA advisory committee recommends approval of Sanofi/AstraZeneca’s RSV vaccine for infants.
FDA Approves Second Bispecific Antibody for Diffuse Large B-cell Lymphoma.
The FDA has given accelerated approval to Genentech’s Columvi (glofitamab-gxbm) to treat adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Large B-cell lymphoma is a fast-growing non-Hodgkin’s lymphoma (NHL) and is one of the most prevalent types of blood cancer among adults in the United States. Patients who relapse have poor outcomes.
Columvi will be available in the United States in the coming weeks. The estimated cost is about $350,000 for a fixed-duration treatment that is intended to be completed in 8.5 months (12 treatment cycles). A Genentech spokesperson said they expect Columvi will be covered by Medicare but it is too early to comment on the specifics. The spokesperson also said they are in discussions with multiple payers to determine insurance coverage of Columvi.
Columvi was approved based on data from the pivotal phase 1/2 NP30179 study. Results showed patients treated with Columvi achieved durable remission, with 56% of patients achieving an overall response and 43% of patients achieving a complete response. The most common adverse events were cytokine release syndrome (70%), musculoskeletal pain (21%), fatigue (20%) and rash (20%). CRS was generally low grade.
FDA Approves Linzess to Treat Children with Constipation.
The FDA has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6 to 17 years-old with functional constipation, which affects an estimated 6 million U.S. children in this age group.
Developed by Ironwood Pharmaceuticals and AbbVie, Linzees Linaclotide is a guanylate cyclase-C (GC-C) agonist that is thought to work in two ways. It binds to the GC-C receptor locally, within the intestinal epithelium. Activation of GC-C results in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine.
The children’s dose is 72 mcg, and Ironwood indicated that this dose is now available with access on most formularies. For adults, the recommended dose is 290 mcg for irritable bowel syndrome patients and 145 mcg for chronic idiopathic constipation patients, with an average retail cost of about $594 for 30 tablets, according to GoodRx.
The FDA approval was based on the results of a phase 3 study evaluating 328 patients 6 to 17 years of age who received Linzess 72 mcg. Linzess showed a statistically significant improvement compared with placebo in 12-week spontaneous bowel movement (SBM) frequency rate (SBMs/week), the primary endpoint. The most common adverse event was diarrhea, which occurred in 4% of Linzess-treated patients.
FDA Committee Recommends Sanofi/AstraZeneca’s RSV Vaccine for Infants.
FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s RSV prevention vaccine nirsevimab has a favorable benefit risk profile for newborns and infants born during or entering their first RSV season. The committee also voted 19 to 2 in support of nirsevimab’s favorable benefit risk profile for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, Sanofi said in a press release.
If approved, nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, including those born healthy at term or preterm, or with specific health conditions that make them vulnerable to RSV disease, according to Sanofi.
Optimize Your Healthcare Payments with Optum Financial
April 29th 2025Discover how Optum Financial is revolutionizing healthcare payments in our latest whitepaper. Learn how transitioning to electronic payments can reduce administrative costs, streamline claims processing and enhance security.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
What 5 Managed Care Trends Experts Say You’re Not Watching Closely Enough
April 29th 2025Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Read More